Perioperative management of patients with hyponatremia requires careful evaluation of etiology, severity, and chronicity, as both hyponatremia and its correction can significantly influence surgical outcomes. Hyponatremia is defined as a serum sodium concentration below 135 mEq/L and is common in patients with chronic diseases such as cirrhosis. It is also associated with increased perioperative morbidity and mortality. In cirrhotic patients, the underlying mechanism involves systemic vasodilation and neurohormonal activation, including increased antidiuretic hormone secretion. This results in impaired free water excretion and dilutional hyponatremia (1). This physiologic disturbance can lead to complications such as hepatic encephalopathy, renal dysfunction, and decreased survival.
Preoperative assessment of hyponatremia should focus on identifying the underlying cause and determining volume status. Hypovolemic hyponatremia is treated with isotonic fluid resuscitation and discontinuation of diuretics. Hypervolemic hyponatremia, which is more common in cirrhosis, is managed with fluid restriction and correction of contributing electrolyte abnormalities, such as hypokalemia (2). The urgency of treatment is guided by symptoms such as nausea, confusion, and seizures. According to expert recommendations, intervention is necessary when patients exhibit symptoms or when serum sodium falls below 120 mEq/L due to increased neurologic risk (1).
A central principle in the perioperative management of hyponatremia is avoiding its rapid correction. Overcorrection of serum sodium can lead to osmotic demyelination syndrome (ODS), a serious neurologic condition characterized by delayed onset of dysarthria, quadriparesis, and altered mental status. Evidence suggests that sodium correction should not exceed 8 mEq/L in a 24-hour period (1). Importantly, ODS risk is more closely related to the rate of correction than the baseline sodium level, and cases have been reported even with moderate hyponatremia.
Intraoperative management poses additional challenges, especially during major procedures such as liver transplantation. Serum sodium levels often rise during surgery due to the administration of isotonic fluids, blood products, and sodium-containing medications (1). Larger intraoperative sodium shifts have been associated with prolonged mechanical ventilation and extended stays in the intensive care unit (1). Strategies to minimize rapid correction include limiting sodium-rich fluids, restricting transfusion volume when feasible, and avoiding sodium bicarbonate. In select cases, continuous renal replacement therapy may be used to control sodium fluctuations.
Pharmacologic therapies for hyponatremia have a limited role in the perioperative setting. Vasopressin receptor antagonists such as tolvaptan promote aquaresis and can raise serum sodium levels but must be used cautiously due to potential hepatotoxicity and limited perioperative data (3). Hypertonic saline is reserved for severe symptomatic hyponatremia, particularly in acute presentations with seizures, and requires close monitoring to prevent overcorrection.
Postoperatively, hyponatremia is associated with increased complications, including infections, renal dysfunction, and neurological events. Although some studies suggest reduced survival, others demonstrate no significant difference compared with normonatremic patients, indicating that outcomes may depend on comorbid conditions and management strategies (4). Overall, maintaining stable sodium levels and avoiding rapid fluctuations remain key priorities.
Perioperative hyponatremia management requires an individualized approach that balances correction with safety. Careful monitoring, gradual sodium correction, and attention to underlying pathophysiology are essential to reducing complications and improving surgical outcomes.
References
1. Leise MD, Findlay JY. Hyponatremia in the perioperative period: when and how to correct. Clin Liver Dis. 2017;9(5):111-114.
2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-S42. doi:10.1016/j.amjmed.2013.07.006
3. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099-2112. doi:10.1056/NEJMoa065181
4. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-1026. doi:10.1056/NEJMoa0801209
Recent Comments